Interrogating Publicly Available Datasets for Biomarker Discovery & Prioritisation
- Presenting a worked example of how data from human cell lines and primary tumours can be leveraged to identify biomarker of response to a compound currently in clinical development
- Discussing biomarker complexity as a consideration for clinical development